CD19 and diffuse large B-cell lymphoma: Partially due to concerns related to CLL-induced immune dysfunction, patients with RS were not included in the pivotal CAR-T cell trials in DLBCL, thus explaining the lack of clinical data regarding the efficacy of anti-CD19 CAR-T [143,144].